Therapeutic Advances in Psychopharmacology最新文献

{"title":"Lithium nephrotoxicity: a systematic review and meta-analysis of lithium versus non-lithium control studies in patients with affective disorders.","authors":"Marie Michele Macaron, Mireilla Abou Rjeily, Raphael Macaron, Asmaa Yehia, Balwinder Singh, Mark A Frye, Osama A Abulseoud","doi":"10.1177/20451253261419633","DOIUrl":"10.1177/20451253261419633","url":null,"abstract":"<p><strong>Background: </strong>Lithium, the gold standard treatment of bipolar disorder (BD), is thought to cause nephropathy in long-term users. However, the role of confounding variables linked to BD in exerting this adverse effect remains unclear.</p><p><strong>Objectives: </strong>This paper evaluates kidney function in patients with affective disorders who are taking lithium compared to patients not on lithium treatment.</p><p><strong>Design: </strong>This article is a systematic review and meta-analysis.</p><p><strong>Data sources and methods: </strong>A comprehensive search of publications up to October 2023 within Cochrane, Embase, PubMed, Scopus, Web of Science, and CINAHL databases was performed. Three assessors screened and extracted data from eligible observational studies. Risk of bias assessment was done with the ROBINS-E tool. Eligible studies were comparative studies of adult patients with diagnoses of affective disorders, including BD on lithium, with control groups not on lithium, reporting kidney function outcomes.</p><p><strong>Results: </strong>Mean estimated Glomerular filtration rate (eGFR) showed less favorable outcomes in the lithium group compared to the non-lithium group (<i>n</i> = 1622, MD = -11.14 ml/min/1.73 m², 95% CI: -16.61, -5.68, <i>I</i> ² = 86%). The mean annual eGFR decline comparison favored the non-lithium group (<i>n</i> = 13,280, MD = 0.13 ml/min/1.73 m², 95% CI: 0.06, 0.20,<i>I</i> ² = 0%). Serum creatinine concentration (mg/dl) was found to be higher in the lithium compared to non-lithium groups (<i>n</i> = = 1704, MD = 0.05, 95% CI: 0.03, 0.07,<i>I</i> ² = 3%). New or progressing chronic kidney disease events were not found to be statistically different between the lithium and control groups (<i>n</i> = = 17,740, OR = 2.16, 95% CI: 0.59, 7.94,<i>I</i> ² = 99%). The high heterogeneity in this meta-analysis limits the reliability and interpretability of our results.</p><p><strong>Conclusion: </strong>Kidney function, as measured by eGFR, was decreased in the lithium-taking groups versus the non-lithium groups. Continuous monitoring and discussion of risks and benefits with patients, especially those with a baseline of reduced kidney function, is imperative.</p><p><strong>Trial registration: </strong>This review was registered prospectively with PROSPERO (CRD42024517414).</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261419633"},"PeriodicalIF":5.0,"publicationDate":"2026-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12921164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare resource savings from administering paliperidone palmitate once every 3 months instead of once every month for schizophrenia: a 12-month mirror-image analysis of real-world population-based data.","authors":"Ke-Fei Wu, Ya-Hui Yang, Chuan-Sheng Hung, Jui-Hsiu Tsai, Hung-Yi Chuang","doi":"10.1177/20451253261419626","DOIUrl":"10.1177/20451253261419626","url":null,"abstract":"<p><strong>Background: </strong>Inadequate adherence to antipsychotic medication remains a major driver of relapse, hospitalization, and chronic disease progression in schizophrenia. Long-acting injectable (LAI) antipsychotics may reduce healthcare costs and the risk of relapse. However, evidence regarding the switch from paliperidone palmitate once every month (PP1M) to paliperidone palmitate once every 3 months (PP3M) remains limited.</p><p><strong>Objectives: </strong>To examine the utilization of LAI antipsychotics and investigate the effect of transitioning from PP1M to PP3M on adherence and healthcare utilization.</p><p><strong>Design: </strong>This retrospective, 12-month mirror-image study used nationwide, population-based data from Taiwan to examine changes in healthcare resource utilization and costs after the transition from PP1M to PP3M.</p><p><strong>Methods: </strong>Individuals with schizophrenia who were newly prescribed PP3M after receiving PP1M for at least 12 months between 2016 and 2021 were included. Healthcare resource utilization and costs during the 12 months before PP3M initiation were compared with those during the 12 months after initiation. Risk factors for an unsuccessful transition from PP1M to PP3M were also identified.</p><p><strong>Results: </strong>Among the 4001 patients with schizophrenia spectrum disorders included in this study, 2790 (69.7%) continued PP3M treatment. A younger age, residence in suburban or rural areas, lower concomitant use of other antipsychotics, and higher use of benzodiazepine were independent risk factors for an unsuccessful transition. At 12 months after PP3M initiation, hospitalization costs decreased from NT$38,469.0 to NT$20,062.8 and emergency room visit costs from NT$692.1 to NT$360.9 (both <i>p</i> < 0.001). The rates of outpatient visits, emergency room visits, and hospitalizations, the length of hospital stay, and total healthcare costs also decreased significantly (all <i>p</i> < 0.001).</p><p><strong>Conclusion: </strong>Transitioning from PP1M to PP3M for schizophrenia treatment can significantly reduce healthcare resource utilization and costs. Notably, hospitalization and emergency room visit costs were reduced by approximately half.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253261419626"},"PeriodicalIF":4.0,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12905104/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146202963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex, drugs, and arousal-two randomized trials on the effects of ketamine on sexual arousal and calcarine gyrus activity.","authors":"Manfred Klöbl, Thomas Liebe, Gregor Dörl, Peter Stöhrmann, Clemens Schmidt, Elisa Briem, Christian Milz, Gabriel Schlosser, Maximilian Kathofer, David Gomola, Godber Mathis Godbersen, Julia Sophia Crone, Rupert Lanzenberger, Marie Spies","doi":"10.1177/20451253251406059","DOIUrl":"10.1177/20451253251406059","url":null,"abstract":"<p><strong>Background: </strong>Ketamine, a well-established antidepressant and dissociative anesthetic, is also used recreationally in the club and chemsex scene. Survey and qualitative data suggest that while ketamine facilitates chemsex encounters, it diminishes the intensity of the sexual experience.</p><p><strong>Objectives: </strong>To investigate this phenomenon from a neuroscientific perspective while considering ketamine's sex-specific effects.</p><p><strong>Design: </strong>Two randomized, placebo-controlled crossover studies using intranasal S-ketamine (double-blinded) or intravenous racemic ketamine (single-blinded).</p><p><strong>Methods: </strong>Subjective sexual arousal in response to a newly compiled set of erotic stimuli was assessed following subacute S-ketamine and late racemic ketamine administration across two studies. Overall, 67 healthy volunteers (26 females) participated in the studies. Functional magnetic resonance imaging (fMRI) was performed during sexual arousal assessment under late racemic ketamine exposure, with both studies also incorporating resting-state fMRI assessments.</p><p><strong>Results: </strong>Subacute S-ketamine reduced sexual arousal to heterosexual stimuli in women (β = -0.21, CI₉₅ = (-0.36, -0.06)) and, to a lesser extent, to lesbian stimuli in men (β = -0.16, CI₉₅ = (0.003, -0.33)). It also diminished sexual aversion to gay stimuli in both sexes (β ⩾ 0.18, CI₉₅ ⩾ (0.03, 0.32)). Conversely, late racemic ketamine decreased sexual arousal to heterosexual stimuli in men (β = -0.17, CI₉₅ = (-0.31, -0.02)) while exacerbating sexual aversion to gay stimuli in women (β = -0.24, CI₉₅=(-0.36,-0.12)). Furthermore, late ketamine administration resulted in reduced calcarine gyrus activation in men compared to women, independent of sexual arousal (β ⩽ -0.23, CI₉₅ ⩽ (-0.52, 0.05)). This finding was confirmed for resting activity under subacute ketamine (β = -0.18, CI₉₅ = (-0.32, -0.04)).</p><p><strong>Conclusion: </strong>Our results align with reports of diminished sexual arousal under ketamine, while the reduced sexual aversion may play a role in facilitating chemsex. The heightened sexual aversion in women and the distinct calcarine gyrus activity modulation may relate to previously documented sex-dependent ketamine effects on stress resilience and psychosis-like symptoms.</p><p><strong>Trial registration: </strong>Both studies were registered at clinicaltrials.gov: NCT05320120 (2022-04-08), NCT05320107 (2022-04-08).</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253251406059"},"PeriodicalIF":4.0,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12901892/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146202120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of treatment with long‑acting injectable antipsychotics on hospitalization and relapse rates in schizophrenia spectrum disorders: a 3‑year follow-up mirror‑image study.","authors":"Renato de Filippis, Matteo Aloi, Alfredo Cimino, Elvira Anna Carbone, Marianna Rania, Ettore D'Onofrio, John M Kane, Georgios Schoretsanitis, Cristina Segura-Garcia, Pasquale De Fazio","doi":"10.1177/20451253251403263","DOIUrl":"10.1177/20451253251403263","url":null,"abstract":"<p><strong>Background: </strong>Long-acting injectable (LAI) antipsychotics are an important treatment option for the long-term treatment management of schizophrenia spectrum disorders (SSDs). Emerging evidences suggest a beneficial impact on long-term treatment outcomes, such as hospitalization and/or relapse risk.</p><p><strong>Objectives: </strong>We aimed to apply a 3-year follow-up mirror observation design to compare relapse as well as hospitalization rates and the number of hospitalization days during the 3 years before and after the start of LAI treatment in a sample of individuals with SSDs in a naturalistic outpatient clinical setting.</p><p><strong>Methods: </strong>We used a 3-year follow-up mirror-image design to compare hospitalization rates and duration, and the total number of clinical relapses in the 3 years before and after initiating LAI treatment in outpatients suffering from SSDs, switching from their oral counterparts.</p><p><strong>Results: </strong>Among 83 individuals screened, 56 adults (females, <i>n</i> = 20, 35.7%) with SSDs who began treatment with either first-generation (FGA) or second-generation (SGA) LAIs were included. Overall, switching from oral to LAI antipsychotic formulations significantly reduced both the number and duration of hospitalizations (from 10.15 to 0.18 average days) in treatment-compliant patients, as well as the overall number of relapses at 3 years of follow-up (from an average of 1.85 to 1.10). In the subgroup analysis, we found a reduced number of hospitalizations during the 3 years follow-up for both patients switched to SGA LAIs and FGA LAIs, but only if receiving LAI treatment for >6 consecutive months. This benefit was only reported in patients switched to LAI for the first time.</p><p><strong>Conclusion: </strong>This study highlights the effectiveness of LAIs as a maintenance treatment for SSDs, particularly for patients with longer LAI treatment duration. Future research may further identify the clinical characteristics of individuals with SSDs who may benefit most from LAI treatment.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253251403263"},"PeriodicalIF":4.0,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12894649/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146201899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Levels of aripiprazole in the blood with an injection of aripiprazole administered once every two months: a plain language summary of publication.","authors":"Yanlin Wang, Matthew Harlin, Frank Larsen, Xiaofeng Wang, Wansu Park, Benjamin Rich, Jogarao V Gobburu, Arash Raoufinia","doi":"10.1177/20451253251414551","DOIUrl":"https://doi.org/10.1177/20451253251414551","url":null,"abstract":"<p><p>What is this summary about? The information summarized here relates to aripiprazole, a medicine that is used to treat conditions such as schizophrenia and bipolar I disorder. Researchers wanted to understand what levels of aripiprazole in the blood looked like following an injection of aripiprazole administered once every 2 months. They did this using a method known as population pharmacokinetics. Why was this research done? Researchers conduct clinical trials when developing new medicines to see how well they work and how safe they are. Clinical trials cannot cover every possible real-life scenario. Researchers can address this by performing population pharmacokinetic modeling and simulation, a process that involves computers and specialized software. Population pharmacokinetic modeling combines information from many people to show how a medicine is absorbed, distributed, broken down, and cleared from the body. It is also done to understand why these processes might vary between people. After the model is built, it can be used to simulate (estimate) the level of the medicine in the blood in situations not tested in clinical trials. What were the results? Simulations showed that an injection of aripiprazole given once every 2 months results in effective drug levels that last until the next dose is due. Drug levels with aripiprazole given once every 2 months are similar to those with injections of aripiprazole given once-monthly, but with fewer injections. What do the results mean? The results provide insight into aripiprazole levels in the blood in people newly starting or continuing treatment with aripiprazole once every 2 months. They add to information already collected in clinical trials. The findings supported the approval of aripiprazole once every 2 months in people living with schizophrenia or bipolar I disorder. They also helped inform the guidance that doctors follow when they prescribe the drug to their patients. The availability of aripiprazole once every 2 months may make treatment easier, and help people stick to their treatment over time.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253251414551"},"PeriodicalIF":4.0,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12873072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146143378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anhedonia nonresponse to short-term ketamine administration for treatment-resistant bipolar depression.","authors":"Zofia Kachlik, Wiesław Jerzy Cubała, Michał Walaszek, Michał Pastuszak, Krzysztof Pastuszak, Aleksander Kwaśny","doi":"10.1177/20451253251412629","DOIUrl":"10.1177/20451253251412629","url":null,"abstract":"<p><strong>Background: </strong>Anhedonia is a key symptom of bipolar depression and a target of ketamine's rapid antidepressant effects. However, many patients with treatment-resistant bipolar depression (TRBD) do not respond.</p><p><strong>Objectives: </strong>This study aimed to identify clinical and sociodemographic characteristics that are associated with nonresponse of anhedonia following short-term ketamine treatment in TRBD.</p><p><strong>Design: </strong>A retrospective analysis using data from two naturalistic, observational registries of 31 patients with TRBD and baseline anhedonia (Snaith-Hamilton Pleasure Scale (SHAPS) > 2). Patients received eight doses of ketamine (IV: 0.5 mg/kg; oral: 2.0-2.5 mg/kg) over a short-term treatment course.</p><p><strong>Methods: </strong>Patients were classified as responders or nonresponders based on a ⩾50% reduction in SHAPS score by the seventh ketamine dose. Groups were compared on baseline sociodemographic and clinical features.</p><p><strong>Results: </strong>Fourteen patients (45.2%) did not respond. Nonresponders had higher BMI, later illness onset, fewer hypomanic episodes, and lower employment rates.</p><p><strong>Conclusion: </strong>Metabolic, illness-course, and psychosocial factors may predict reduced anti-anhedonic response to ketamine in TRBD.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253251412629"},"PeriodicalIF":4.0,"publicationDate":"2026-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12861376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146107395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjunctive treatment with evenamide, a glutamate modulator, is associated with clinically meaningful benefits in patients with treatment-resistant schizophrenia and inadequate response to antipsychotics: recent clinical findings from randomized trials.","authors":"Ravi Anand, Alessio Turolla, Giovanni Chinellato, Francesca Sansi, Arjun Roy, Richard Hartman","doi":"10.1177/20451253251414529","DOIUrl":"https://doi.org/10.1177/20451253251414529","url":null,"abstract":"<p><strong>Background: </strong>Despite their efficacy in improving positive symptoms, first- and second-generation antipsychotics (FGAs and SGAs) fail to provide benefit to a large portion of patients with schizophrenia. Evenamide, uniquely acting at the site of dysfunction, normalizes hippocampal glutamatergic aberrant activity and reduces downstream hyperdopaminergic state, potentially alleviating also negative and cognitive symptoms, and providing benefit to patients with treatment-resistant schizophrenia (TRS) or inadequate response to antipsychotics (APs).</p><p><strong>Objectives: </strong>Evaluate the clinical benefits of glutamate modulation through evenamide as an add-on treatment to FGAs and SGAs in patients with TRS or inadequate response to APs.</p><p><strong>Design: </strong>Post-hoc analyses of results from two phase II/III clinical trials with evenamide add-on to antipsychotic treatment.</p><p><strong>Methods: </strong>Data from Study 014/015, an open-label, 1-year trial in patients with TRS, was analyzed to assess the proportion of patients no longer meeting the baseline severity criteria for TRS (modified Intent-to-Treat (mITT) population; Observed Cases (OC)) and the proportion of patients in the mITT population achieving remission. Data from Study 008A, a randomized, double-blind, placebo-controlled, 4-week trial in patients with schizophrenia not adequately benefiting from SGA (including clozapine), was analyzed to assess patients' response according to the number of previously failed AP attempts (ITT population; mixed model repeated measures (MMRM) linear regression model). The effect of evenamide on social functioning and life engagement was evaluated in both studies (mITT population) using an MMRM linear regression model for Study 008A and an OC analysis for Study 014/015.</p><p><strong>Results: </strong>Patients with TRS receiving evenamide add-on for 1-year improved to such an extent that 55% of them no longer satisfied baseline TRS severity criteria, and approximately one-fourth achieved remission according to literature criteria (27.6% Lieberman et al., 1993; 25.0% Andreasen et al., 2005). In Study 008A, irrespective of the number of failed APs, a statistically significant drug-placebo difference was observed in patients with a single failed attempt (-4.9, <i>p</i> = 0.0122) and in those with 2 or more failed attempts (-2.36, <i>p</i> = 0.0311). Moreover, add-on treatment with evenamide in Study 014/015 was associated with a progressive improvement on the PANSS subdomains of social functioning and life engagement. In Study 008A as well, evenamide resulted in a greater effect, compared to placebo, on the same subdomains.</p><p><strong>Conclusion: </strong>Add-on treatment with evenamide to APs (including clozapine) was associated with clinically meaningful and progressive long-term benefits across numerous post-hoc analyses including improvements on patient's daily life and functioning.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253251414529"},"PeriodicalIF":4.0,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12835518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146094249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A description of antipsychotic prescribing patterns on the inpatient behavioral health setting: a multicenter cross-sectional analysis.","authors":"Thomas Maestri, David Anderson, Margarita Echeverri","doi":"10.1177/20451253251394296","DOIUrl":"10.1177/20451253251394296","url":null,"abstract":"<p><strong>Background: </strong>Antipsychotic therapy can bring a great deal of benefit to individuals with schizophrenia and other psychiatric diagnoses, though this class of medications is also associated with intolerabilities due to possible adverse events. Notable adverse events commonly experienced include movement disorders and metabolic concerns that can occur even at low doses and minimal exposure.</p><p><strong>Objectives: </strong>Describe the prescribing patterns of antipsychotics in the inpatient behavioral health setting, and report on characteristics that lead to populations having higher or lower dosing exposures to antipsychotic therapy that follows FDA guidelines.</p><p><strong>Design: </strong>Multicentered, retrospective, cross-sectional chart review.</p><p><strong>Methods: </strong>The study was conducted at two academic hospitals in the inpatient behavioral health setting. Information was collected on 785 cases of patients who were hospitalized during the study period with a psychiatric diagnosis that necessitated a prescription for an antipsychotic medication at the time of discharge. Differences in antipsychotic drug (dose, type, number, and duration of treatment) were characterized, and data were collected on clinician adherence to FDA guidance, as listed in the package insert of each antipsychotic drug. Primary outcomes were the amount of Total Chlorpromazine Equivalent Dosing doses and the clinician's adherence to FDA guidance.</p><p><strong>Results: </strong>This study found that the male gender (<i>p</i> < 0.0001), no social support (<i>p</i> < 0.0025), more previous antipsychotic trials (<i>p</i> < 0.0001), and longer hospital stays (<i>p</i> < 0.0001) were statistically significant for patients receiving higher antipsychotic doses at discharge. Additionally, patients with comorbid diabetes (<i>p</i> < 0.0001), more antipsychotics at discharge (<i>p</i> = 0.001), and Medicare insurance (<i>p</i> = 0.005) were less likely to receive antipsychotic medication following FDA recommendations and current guidelines.</p><p><strong>Conclusion: </strong>The results of this study can inform practice regarding antipsychotic prescribing patterns in different populations. Conducting prospective studies across a broader range of institutions, it is recommended to better understand the relationship between patient demographics and prescribing patterns during periods of acute illness.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"16 ","pages":"20451253251394296"},"PeriodicalIF":4.0,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12779905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145953105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute and persistent withdrawal syndromes following discontinuation of antidepressants in children and adolescents: a systematic review.","authors":"Jianjun Wang, Fiammetta Cosci","doi":"10.1177/20451253251404780","DOIUrl":"10.1177/20451253251404780","url":null,"abstract":"<p><p>Antidepressants are commonly prescribed for children and adolescents, but their discontinuation may result in withdrawal symptoms, though rarely described for this age group in the literature. Systematically examining the types and prevalence of withdrawal syndromes in children and adolescents in accordance with PRISMA guidelines is the aim of the present paper. A search of PubMed, Embase, Web of Science, and Cochrane Library was conducted from inception to December 2024. Inclusion criteria were: clinical populations; subjects aged 2-18; antidepressant discontinuation; assessment of withdrawal symptoms; randomized controlled trials (RCTs) or observational studies; rate/type of withdrawal symptoms. A total of 6227 citations were screened, leading to 12 studies, encompassing 690 participants aged 2-18 years, with eight RCTs and four observational studies. The analysis revealed common withdrawal symptoms across various antidepressant classes, predominantly affecting the central nervous and gastrointestinal systems. Symptoms such as nausea (14.6%-22.0%), headache (14.6%-15.0%), diarrhea (10.0%-22.0%), depression (10%), inner tension (44%), anxiety/worry (44%), and cough (33%) were frequently observed, especially after discontinuation of selective serotonin reuptake inhibitors. Such symptoms clustered in new withdrawal symptoms according to a diagnostic classification of withdrawal syndromes at discontinuation of antidepressants used in adults. Withdrawal symptoms and withdrawal syndromes following antidepressant discontinuation in children and adolescents are still neglected but pose significant clinical challenges, often resembling or exacerbating underlying conditions. Future research is needed, as well as a systematic assessment of these symptoms in the clinical realm (registered in OSF DOI: https://doi.org/10.17605/OSF.IO/GYQ9Z).</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251404780"},"PeriodicalIF":4.0,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12722687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145828441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.","authors":"Serene Lee, Liyang Yin, Kayla M Teopiz, Sabrina Wong, Gia Han Le, Naomi Xiao, Stephen Stahl, Kyle Valentino, Roger Ho, Melanie C Zhang, Taeho Greg Rhee, Roger S McIntyre","doi":"10.1177/20451253251396304","DOIUrl":"10.1177/20451253251396304","url":null,"abstract":"<p><p>Extant literature pertaining to the administration of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for Alzheimer's disease, Parkinson's disease, major depressive disorder, bipolar disorder, substance-, alcohol- and nicotine-use disorders, suggests promising efficacy beyond the current FDA-approved indications (e.g., type 2 diabetes mellitus, obesity). The implicated brain regions of the aforementioned mental disorders contain glucagon-like peptide 1 (GLP-1) receptors associated with improving cognitive and behavioral functioning. Therefore, we aimed to systematically review the treatment effects of GLP-1RAs in various neurocognitive and psychiatric disorders. Online databases including PubMed, OVID, MEDLINE, Embase, PsycINFO and Google Scholar, were searched from inception until October 1, 2024. Additional studies were identified from the reference lists of the included articles. 22 studies were identified, with a total of 186,847 participants included. Results reported that GLP-1RAs meaningfully improved cognitive and affective functioning (e.g., memory), which in some cases was sustained beyond exposure to the agent. Separately, multiple epidemiological studies reported that GLP-1RAs have protective effects, with a suggestion of decrease in the incidence of mental disorders. These results provides the impetus for large, long-term, randomized controlled trials for GLP-1 RAs for the treatment of various mental disorders. This review is not registered in PROSPERO or any other registry.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"15 ","pages":"20451253251396304"},"PeriodicalIF":4.0,"publicationDate":"2025-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12722685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145828431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}